Sequential transcatheter arterial chemoembolization and portal vein embolization before right hemihepatectomy in patients with hepatocellular carcinoma

• Published in: Hepatobiliary & pancreatic diseases international 2020-06, Vol.19 (3), p.244-251
• Main Authors: Park, Gil Chun, Lee, Sung Gyu, Yoon, Young In, Sung, Kyu Bo, Ko, Gi Young, Gwon, Dong Il, Jung, Dong Hwan, Jung, Yong Kyu
• Format: Article
• Language: English
• Subjects: Adult; Antineoplastic Agents - administration & dosage; Arterial chemoembolization; Carcinoma, Hepatocellular - pathology; Carcinoma, Hepatocellular - therapy; Chemoembolization, Therapeutic; Cisplatin - administration & dosage; Combined Modality Therapy; Disease-Free Survival; Ethiodized Oil - administration & dosage; Female; Future liver remnant; Hepatectomy; Hepatocellular carcinoma; Humans; Liver Neoplasms - pathology; Liver Neoplasms - therapy; Liver Regeneration; Male; Middle Aged; Neoplasm Recurrence, Local - pathology; Portal Vein; Portal vein embolization; Preoperative Period; Retrospective Studies; Sequential selective transcatheter; Survival Rate
• ISSN: 1499-3872
• DOI: 10.1016/j.hbpd.2020.04.008

Recent studies showed that sequential selective transcatheter arterial chemoembolization (TACE) and portal vein embolization (PVE) provided better future liver remnant (FLR) regeneration rate and disease-free survival following surgery compared with PVE alone. The present study aimed to clarify whether preoperative sequential TACE and PVE before right hemihepatectomy can reduce postoperative hepatocellular carcinoma (HCC) recurrence and improve long-term disease-free and overall survival. Recurrence and survival outcomes were retrospectively evaluated in 205 patients with HCC who underwent right hemihepatectomy by a single surgeon from November 1993 to November 2017. Patients were divided into four groups according to the procedure performed before the surgery: sequential TACE and PVE (TACE-PVE), PVE-only, TACE-only, or naïve control groups. The baseline patient and tumor characteristics, postoperative outcomes, recurrence-free survival and overall survival were analyzed. Baseline patient and tumor characteristics upon diagnosis were similar in all four groups, while sequential TACE and PVE were well tolerated. The TACE-PVE group had a higher mean increase in percentage FLR volume compared with that of the PVE-only group (17.46% ± 6.63% vs. 12.14% ± 5.93%; P = 0.001). The TACE-PVE group had significantly better overall and disease-free survival rates compared with the other groups (both P